BREEZE-AD5 Study Results: Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis

From the 2020 Annual Meetings of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Dermatology (AAD), and Revolutionizing Atopic Dermatitis (RAD).
Significantly improved skin inflammation, pain, itch, sleep, and quality-of-life outcomes in patients with moderate to severe AD treated with baricitinib vs placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 160 KB
Released: August 11, 2020

Acknowledgements

Provided by Clinical Care Options.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This educational activity is supported by educational grants from
AbbVie Inc.
Pfizer, Inc.

Related Content

From Clinical Care Options (CCO) and Dr. Robert Sidbury, expert commentary on new data in atopic dermatitis evaluation and management.

Robert Sidbury, MD, MPH Released: June 30, 2021

Assessment of antipruritic properties of ruxolitinib cream using pooled data from TRuE-AD1 and TRuE-AD2: atopic dermatitis conference coverage from Clinical Care Options (CCO)

Released: June 18, 2021

Assessment of depth, rapidity of response of abrocitinib and dupilumab in patients with moderate to severe AD in JADE COMPARE using stringent endpoints: atopic dermatitis conference coverage from Clinical Care Options (CCO)

Released: June 15, 2021

Characterization of skin pain in children with atopic dermatitis: atopic dermatitis conference coverage from Clinical Care Options (CCO)

Released: June 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue